Integrated Biopharma Files Definitive Proxy Statement
Ticker: INBP · Form: DEF 14A · Filed: Oct 28, 2024 · CIK: 1016504
| Field | Detail |
|---|---|
| Company | Integrated Biopharma Inc (INBP) |
| Form Type | DEF 14A |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, corporate-governance
TL;DR
IBP filed its proxy statement - shareholders vote soon.
AI Summary
Integrated Biopharma, Inc. filed a definitive proxy statement (DEF 14A) on October 28, 2024. The filing pertains to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company, previously known as Integrated Health Technologies Inc. and Chem International Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for upcoming shareholder meetings, allowing them to make informed voting decisions on the company's governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial information or strategic announcements that would inherently increase risk.
Key Players & Entities
- INTEGRATED BIOPHARMA, INC. (company) — Registrant
- INTEGRATED HEALTH TECHNOLOGIES INC (company) — Former Company Name
- CHEM INTERNATIONAL INC (company) — Former Company Name
- 20020912 (date) — Date of Name Change
- 19960716 (date) — Date of Name Change
- 20241028 (date) — Filing Date
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing information about matters to be voted upon.
When was Integrated Biopharma, Inc. previously known by other names?
Integrated Biopharma, Inc. was formerly known as Integrated Health Technologies Inc. after a name change on September 12, 2002, and prior to that, as Chem International Inc. after a name change on July 16, 1996.
What is the industry classification for Integrated Biopharma, Inc.?
Integrated Biopharma, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
On what date was this definitive proxy statement filed?
This definitive proxy statement (DEF 14A) was filed on October 28, 2024.
Where is Integrated Biopharma, Inc. located?
Integrated Biopharma, Inc. is located at 225 Long Avenue, Building 15, Hillside, New Jersey, 07205.
Filing Stats: 4,775 words · 19 min read · ~16 pages · Grade level 10.6 · Accepted 2024-10-28 16:13:22
Filing Documents
- inbp20241023_def14a.htm (DEF 14A) — 496KB
- ibp_logo.jpg (GRAPHIC) — 12KB
- 0001437749-24-032295.txt ( ) — 514KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information regarding the number of shares of Common Stock of Integrated BioPharma, Inc. beneficially owned on October 15, 2024, by: each person who is known by the Company to beneficially own five percent (5%) or more of the Common Stock of the Company; each of the directors and executive officers of the Company; and all of the Company's directors and executive officers, as a group. Number of Shares Percent of Shares Name of Beneficial Owne r (1) Beneficially Owned ( 2 ) Beneficially Owned ( 3 ) William H. Milmoe 13,335,558 (4) 43.6% Dean DeSantis 12,784,391 (5) 42.5% Carl DeSantis Revocable Trust 12,766,982 (6) 42.4% Deborah DeSantis 12,766,982 (7) 42.4% Riva Sheppard 5,464,679 (8) 17.7% Christina Kay 5,448,979 (9) 17.7% Heidi Kay 5,019,161 (10) 16.7% Estate of E Gerald Kay 3,393,815 11.3% Dina L Masi 812,200 (12) 2.6% Robert Canarick 646,733 (13) 2.1% Eric Friedman 212,500 (14) 0.7% Damon DeSantis 122,500 (15) 0.4% Directors and executive officers as a group (7 persons) 22,639,334 (16) 67.2% 5 (1) The address of each of the persons listed is c/o Integrated BioPharma Inc., 225 Long Avenue, Hillside, New Jersey 07205. (2) Unless otherwise indicated, includes shares owned by a spouse, minor children, by relatives sharing the same home, and entities owned or controlled by the named person. Also includes shares if the named person has the right to acquire such shares within 60 days after October 15, 2024, by the exercise of warrant, stock option or other right. Unless otherwise noted, shares are owned of record and beneficially by the named person. (3) Based upon 30,099,610 shares of Common Stock outstanding on October 15, 2024. (4) Includes (i) 2,242,809 shares owned by Carl DeSantis Revocable Trust (the "CDC Trust") of which Mr. Milmoe is one of the three co-trustees; (ii)